

CURRICULUM VITAE
ZHI DONG JIANG, MD, DrPh
09-10-2018

Business Address:

The University of Texas Health Science Center at Houston
School of Public Health
Center for Infectious Diseases
P.O. Box 20186, Houston, TX 77225
Voice Mail: (713) 500-9371
Fax: (713) 500-9364

Education:

1998 Doctor of Public Health, The University of Texas Health Science Center School of Public Health, Houston TX
1994 Master of Public Health, The University of Texas Health Science Center School of Public Health, Houston TX
1983 Doctor of Medicine Beijing Medical University, Beijing, China

Current Professional Appointment:

2008 – Present Associate Professor of Epidemiology, Division of Epidemiology, Human Genetics and Environmental Sciences (EGES) and the Center for Infectious Disease The University of Texas School of Public Health, Houston, TX
2000 – Present Director in the Laboratory for Enteric Infectious Disease Research, Center for Infectious Diseases, The University of Texas Health Science Center School of Public Health, Houston TX

Previous Professional Appointment:

1999 – 2008 Assistant Professor of Epidemiology, EGES and in the Center for Infectious Disease, The University of Texas Health Science Center School of Public Health, Houston, TX
1996 – 1998 Senior Research Assistant in the Center for Infectious Disease The University of Texas Health Science Center School of Public Health Houston TX

1995 – 1996	Senior project coordinator in the Department of Surgery Baylor College of Medicine, Houston TX
1994 – 1995	Research data manager in the Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston TX
1988 – 1994	Research Fellow in the Department of Internal Medicine, The University of Texas Health Science Center Medical School Houston TX
1983 – 1988	Pediatrician in the Department of Infectious Diseases Capital Pediatric Institute Beijing China

Other Appointments and Activities at the University of Texas School of Public Health

2000-Present	Radiation Safety Committee
2002-Present	Admission Committee, EHGES
2011-Present	Course Director: Disease: Natural History, Prevention and Control Co-Director: Genetics and Infectious Diseases

Director of Summer Research Program for Students (College and Graduate School)

2010-Present	List of students: Chloe Hamrick (Ohio Wesleyan University), Allison Ramsey (University of Texas Medical School-Houston), Cynthia Oben (University of Texas GSBS), Bradley Turnwald (Ohio Wesleyan University), Asa Schnaekel (University of Texas GSBS), Alan Massouth (Ohio Wesleyan University), Eduardo Mulanovich (St. Thomas University), Daniel Chu (University of Texas Medical School – Houston), Ann Chu (Rice University), Aline Cenoz (University of Texas Medical School – Houston), Ly Hoang (University of Texas Medical School – Houston), Khadijah Bilal (University of Houston), Lauren Kattchee (Brown University), Casey Smiley (Ohio Wesleyan University), Alexander Hanania (University of Texas Medical School – Houston)
--------------	---

Professional and Community Service

2000-Present	Regular scientific reviewer for Journal of Infectious Diseases, Epidemiology and Infection, and the Journal of Travel Medicine
2000-Present	Consultation with Houston City Health Department on Foodborne Infections
2005-Present	Member of the Task Force on <i>Clostridium difficile</i> Infection at St. Luke’s Episcopal Hospital

2006-Present	Collaborative Research with the Human Genetics Center, Baylor College of Medicine in studies dealing with microbiome of the gut
2010-Present	Instructor on Science and Biology for Houston High Schools

Active Grants and Contracts on Which Dr. Jiang is an Investigator

Epidemiology Studies to further Characterize the International Epidemiology of ETEC- and Shigella-associated, moderate-severe travelers' diarrhea (MSTD)

Start/End Date	06-06-2019 to 12-18-2019
Funding Agency/Role/Status	Sanofi Pasteur/PI/Funded
Direct Costs/ Indirect Costs	\$64,710 / \$34,943

A multiplexed diagnostic immunoassay for clostridium difficile and antibiotic-associated diarrhea

Start/End Date	09-14-2015 to 09-13-18
Funding Agency/Role/Status	Radix/NIH/PI/Funded
Direct Costs/ Indirect Costs	\$210,756/\$109,475

An Open-Label Safety Assessment of Rebiotix RBX260 (microbiota suspension) for the Treatment of Recurrent Clostridium Difficile Infection

Start/End Date	07/31/2015 – 07/30/2020
Funding Agency/Role/Status	Rebiotix/Co-Investigator/Funded
Direct Costs/ Indirect Costs	\$469,260 / \$140,778

Publications, Abstracts Excluded (underline indicates student/trainee projects)

Original Peer Scientific Publications

1. **Jiang ZD**, Nelson AC, Mathewson JJ, Ericsson CD, DuPont HL. Intestinal secretory immune response to infection with *Aeromonas* species and *Plesiomonas shigelloides* among students from the United States in Mexico. *Journal of Infectious Diseases* 1991;164:979-982
2. Mathewson JJ, **Jiang ZD**, DuPont HL, Chintu C, Luo N, Zumla A. Intestinal secretory IgA immune response against human immunodeficiency virus among infected patients with acute and chronic diarrhea. *Journal of Infectious Diseases* 1994;169:614-617
3. **Jiang ZD**, Smith MA, Kelsey K, DuPont HL, Mathewson JJ. Effects of storage time and temperature on fecal leukocytes and occult blood in the evaluation of travelers' diarrhea. *Journal of Travel Medicine* 1994;1:184-186
4. Mathewson JJ, **Jiang ZD**, Zumla A, Chintu C, Luo N, Calamari SR, Genta RM, Ateephen A, Schwartz P, DuPont HL. HEp-2 cell adherent *E. coli* in patients with human immunodeficiency virus associated diarrhea. *Journal of Infectious Diseases* 1995;171:1636-1639

5. Plestis KA, Loubser P, Mizrahi EM, Kantis G, **Jiang ZD**, Howell JF. Continuous electroencephalographic monitoring and selective shunting reduces neurologic morbidity rates in carotid endarterectomy. *J Vasc Surg* 1997;25:620-628
6. Plestis KA, **Jiang ZD**, Appel H, Howell JF. Treatment of recurrent carotid disease report on a 12-year experience. *Vascular Surgery* 1997;31:693-701
7. Mathewson JJ, Salameh BM, DuPont HL, **Jiang ZD**, Nelson AC, Arduino R, Smith A, Masozera N. HEp-2 cell adherent *Escherichia coli* and intestinal secretory immune response to human immunodeficiency virus (HIV) in outpatients with HIV-associated diarrhea. *Clinical and Diagnostic Laboratory Immunology* 1998;5:87-90
8. DuPont HL, Ericsson CD, Mathewson JJ, Palazzini E, DuPont MW, **Jiang ZD**, Mosavi A, Cabada FJ. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea. *Digestion* 1998;59:708-714
9. Plestis KA, Ke S, **Jiang ZD**, Howell JF. Combined carotid endarterectomy and coronary artery bypass: immediate and long-term results. *Ann Vasc Surg* 1999;13:84-92
10. Caeiro JP, Mathewson JJ, Smith MA, **Jiang ZD**, Kaplan MA, DuPont HL. Etiology of outpatient pediatric nondysenteric diarrhea: a multicenter study in the United States. *Pediatric Infectious Diseases J* 1999;18:94-97
11. Glandt M, Adachi JA, Mathewson JJ, **Jiang ZD**, Cesare D, Ashley D, Ericsson CD, DuPont HL. Enteroaggregative *Escherichia coli* as a cause of travelers' diarrhea: Clinical response to ciprofloxacin. *Clinical Infectious Diseases* 1999;29:335-338
12. Caeiro JP, Estrada-Garcia M, **Jiang ZD**, Mathewson JJ, Adachi JA, Steffen R, DuPont HL. Improved detection of enterotoxigenic *Escherichia coli* among patients with travelers' diarrhea by using polymerase chain reaction technique. *Journal of Clinical Microbiology* 1999;180:2053-2055
13. **Jiang ZD**, Mathewson JJ, Ericsson CD, Svennerholm AM, Pulido C, DuPont HL. Characterization of enterotoxigenic *Escherichia coli* (ETEC) strains in patients with travelers' diarrhea acquired in Guadalajara, Mexico, 1992 through 1997. *Journal of Infectious Diseases* 2000;181:779-782
14. Paredes P, Campbell-Forrester S, Mathewson JJ, Ashley D, Thompson S, Steffen R, **Jiang ZD**, Svennerholm AM, DuPont HL. Etiology of travelers' diarrhea on a Caribbean island. *Journal of Travel Medicine*. 2000;7:15-18.
15. Sutjita M, Bouckenoghe AR, Adachi JA, **Jiang ZD**, Mathewson JJ, Ericsson CD, DuPont HL. Intestinal secretory immunoglobulin A response to enteroaggregative *Escherichia coli* in travelers with diarrhea. *Clinical and Diagnostic Laboratory Immunology* 2000;7:501-503
16. Adachi JA, **Jiang ZD**, Cox MA, Wood L, DuPont HL, Mathewson JJ. Serum antibody response induced in mice after oral administration of three different antigens of enterotoxigenic *Escherichia coli* in enteric coated microparticles. *Journal of Travel Medicine* 2000;7:304-308

17. **Jiang ZD**, Ke S, Riopel LM, Palazzini E, DuPont HL. Rifaximin therapy of travelers' diarrhea: In vitro activity and fecal concentration after oral administration. *Antimicrobial Agents and Chemotherapy* 2000;44:2205-2206
18. Bouckenooghe AR, DuPont HL, **Jiang ZD**, Adachi J, Mathewson JJ, Steffen R. Markers of enteric inflammation in enteroaggregative *Escherichia coli* diarrhea in travelers. *American Journal of Tropical Medicine and Hygiene* 2000;62:711-713
19. Adachi JA, **Jiang ZD**, Mathewson JJ, Verenkar MP, Thompson S, Steffen R, Ericsson CD, DuPont HL. Enteroaggregative *Escherichia coli* as a major etiologic agent in traveler's diarrhea in 3 regions of the world. *Clinical Infectious Diseases* 2001; 32:1706-1709
20. Gomi H, **Jiang ZD**, Adachi JA, Ashley D, Lowe B, Verenkar MP, Steffen R, DuPont HL. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing travelers' diarrhea in four geographic regions. *Antimicrobial Agents and Chemotherapy* 2001;45:212-216
21. DuPont HL, **Jiang ZD**, Ericsson CD, Adachi JA, Mathewson JJ, DuPont MW, Palazzini E, Riopel LM, Ashley D, Martinez-Sandoval F. Rifaximin versus ciprofloxacin for the treatment of travelers' diarrhea: A randomized, double-blind clinical trial. *Clinical Infectious Diseases* 2001;33:1807-1815
22. Huang BD, **Jiang ZD**, Ericsson CD, Adachi J, DuPont HL. Emergence of trimethoprim-resistant *Escherichia coli* in healthy persons in the absence of prophylactic or therapeutic antibiotics during travel to Guadalajara, Mexico. *Scandinavian Journal of Infectious Diseases* 2001;33:812-814
23. Cardin VA, Grimes RM, **Jiang ZD**, Pomeroy N, Harrell L, Cano P. Low-income minority women at risk for cervical cancer: a process to improve adherence to follow-up recommendations. *Public Health Rep* 2001;116:608-616
24. **Jiang ZD**, Lowe B, Verenkar MP, Ashley D, Steffen R, Tomieporth N, von Sonnenburg F, Waiyaki P, DuPont HL. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa) and Jamaica (Montego Bay). *Journal of Infectious Diseases* 2002;185:497-502
25. Greenberg DE, **Jiang ZD**, Steffen R, Verenker MP, DuPont HL. Markers of inflammation in bacterial diarrhea among travelers with a focus on enteroaggregative *Escherichia coli* pathogenicity. *Journal of Infectious Diseases* 2002;185:944-949
26. Adachi JA, Ericsson CD, **Jiang ZD**, DuPont MW, DuPont HL. Natural History of Enteroaggregative and Enterotoxigenic *Escherichia coli* Infection Among U.S. Travelers to Guadalajara, Mexico. *Journal of Infectious Diseases* 2002;185:1681-1683
27. Miqdady MS, **Jiang ZD**, Nataro JP, DuPont HL. Detection of enteroaggregative *E. coli* (EAEC) employing formalin preserved HEp-2 cells. *Journal of Clinical Microbiology*. 2002;40:3066-3067

28. **Jiang ZD**, Greenberg D, Nataro JP, Steffen R, DuPont HL. Occurrence and pathogenic effect of enteroaggregative *E. coli* virulence factors in international travelers. *Journal of Clinical Microbiology* 2002;40:4185-4190
29. Bouckenooghe AR, **Jiang ZD**, De La Cabada FJ, Ericsson CD, DuPont HL. Enterotoxigenic *Escherichia coli* as cause of diarrhea among Mexican adults and US travelers in Mexico. *Journal of Travel Medicine*. 2002;9:137-140
30. Adachi JA, Mathewson JJ, **Jiang ZD**, Ericsson CD, DuPont HL. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. *Annals of Internal Medicine*. 2002;136:884-887
31. Estrada-Garcia MT, **Jiang ZD**, Adachi J, Mathewson JJ, DuPont HL. Intestinal immunoglobulin a response to naturally acquired enterotoxigenic *Escherichia coli* in US travelers to an endemic area of Mexico. *Journal of Travel Medicine*. 2002;9:247-250.
32. **Jiang ZD**, Okhuysen PC, Guo DC, He R, King TM, DuPont HL, Milewicz DM. Genetic susceptibility to enteroaggregative *Escherichia coli* diarrhea: polymorphism in the interleukin-8 promoter region. *Journal of Infectious Diseases*. 2003;188:506-511
33. Steffen R, Sack DA, Riopel L, **Jiang ZD**, Sturchler M, Ericsson CD, Lowe B, Waiyaki P, White M, DuPont HL. Therapy of travelers' diarrhea with rifaximin on various continents. *American Journal of Gastroenterology*. 2003;98:1073-1078
34. Adachi JA, Ericsson CD, **Jiang ZD**, DuPont MW, Martinez-Sandoval F, Knirsch C, DuPont HL. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. *Clinical Infectious Diseases* 2003;37:1165-1171
35. Huang DB, **Jiang ZD**, DuPont HL. Association of virulence factor-positive and -negative enteroaggregative *Escherichia coli* and occurrence of clinical illness in travelers from the United States to Mexico. *American Journal of Tropical Medicine and Hygiene* 2003;69:506-508.
36. Huang DB, Okhuysen PC, **Jiang ZD**, DuPont HL. Enteroaggregative *Escherichia coli*: an emerging enteric pathogen. *American Journal of Gastroenterology*. 2004;99:383-389.
37. Huang DB, Sanchez AP, Triana E, **Jiang ZD**, DuPont HL, Ericsson CD. United States male students who heavily consume alcohol in Mexico are at greater risk of travelers' diarrhea than their female counterparts. *Journal of Travel Medicine* 2004;11:143-145.
38. Huang DB, DuPont HL, **Jiang ZD**, Carlin L, Okhuysen PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic *Escherichia coli*. *Clinical and Diagnostic Laboratory Immunology* 2004;11:548-551.
39. DuPont HL, **Jiang ZD**. Influence of rifaximin treatment on susceptibility of intestinal gram-negative flora and enterococci. *Clinical Microbiology Infectious* 2004;10:1009-1011

40. Okhuysen PC, **Jiang ZD**, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. *American Journal Gastroenterology* 2004;99:1774-1778
41. Huang DB, DuPont HL, **Jiang ZD**, Carlin L, Okhuysen PC. Interleukin-8 response in an intestinal HCT-8 cell line infected with enteroaggregative and enterotoxigenic *Escherichia coli*. *Clinical and Diagnostic Laboratory Immunology* 2004;11:548-551
42. Infante RM, Ericsson CD, **Jiang ZD**, Ke S, Steffen R, Riopel L, Sack DA, DuPont HL. Enteroaggregative *Escherichia coli* diarrhea in travelers: response to rifaximin therapy. *Clinical Gastroenterology and Hepatology* 2004;2:135-138
43. Ko G, Garcia C, **Jiang ZD**, Okhuysen PC, Belkind-Gerson J, Glass RI, DuPont HL. Noroviruses as a cause of traveler's diarrhea among students from the United States visiting Mexico. *Journal Clinical Microbiology* 2005;43:6126-6129
44. DuPont HL, **Jiang ZD**, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin. *Clinical Infectious Diseases* 2005;41 Suppl 8:S571-S576
45. DuPont HL, **Jiang ZD**, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. *Annals of Internal Medicine* 2005 May 17;142(10):805-12
46. Taylor DN, Bourgeois AL, Ericsson CD, Steffen R, **Jiang ZD**, Halpern J, Haake R, DuPont HL. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. *American Journal of Tropical Medicine and Hygiene* 2006;74:1060-1066
47. Garey KW, Graham G, Gerard L, Dao T, **Jiang ZD**, Price M, DuPont HL. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. *The Annals of Pharmacotherapy*. 2006;40:1030-1034
48. Ko G, **Jiang ZD**, Okhuysen PC, DuPont HL. Fecal cytokines and markers of intestinal inflammation in international travelers with diarrhea due to Noroviruses. *Journal of Medical Virology* 2006;78:825-828
49. **Jiang ZD**, DuPont HL, Garey K, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M. A common polymorphism in the interleukin 8 gene promoter is associated with *Clostridium difficile* diarrhea. *American Journal of Gastroenterology* 2006;101:1112-1116
50. Turner SM, Chaudhuri RR, **Jiang ZD**, DuPont H, Gyles C, Penn CW, Pallen MJ, Henderson IR. Phylogenetic comparisons reveal multiple acquisitions of the toxin genes by enterotoxigenic *Escherichia coli* strains of different evolutionary lineages. *Journal of Clinical Microbiology* 2006;44:4528-4536.

51. Mohamed JA, Huang DB, **Jiang ZD**, DuPont HL, Nataro JP, Belkind-Gerson J, Okhuysen PC. Association of putative enteroaggregative *Escherichia coli* virulence genes and biofilm production in isolates from travelers to developing countries. *Journal of Clinical Microbiology* 2007;45:121-126
52. Mohamed JA, DuPont HL, **Jiang ZD**, Belkind-Gerson J, Figueroa JF, Armitige LY, Tsai A, Nair P, Martinez-Sandoval FJ, Guo DC, Hayes P, Okhuysen PC. A novel single-nucleotide polymorphism in the lactoferrin gene is associated with susceptibility to diarrhea in North American travelers to Mexico. *Clinical Infectious Diseases* 2007;44:945-952.
53. Huang DB, Mohamed JA, Nataro JP, DuPont HL, **Jiang ZD**, Okhuysen PC. Virulence characteristics and the molecular epidemiology of enteroaggregative *Escherichia coli* isolates from travellers to developing countries. *Journal of Medical Microbiology* 2007;56:1386-1392
54. Ericsson CD, DuPont HL, Okhuysen PC, **Jiang ZD**, DuPont MW. Loperamide plus azithromycin more effectively treats travelers' diarrhea in Mexico than azithromycin alone. *Journal of Travel Medical* 2007;14:312-319
55. **Jiang ZD**, Garey KW, Price M, Graham G, Okhuysen P, Dao-Tran T, LaRocco M, DuPont HL. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with *Clostridium difficile*-associated diarrhea. *Clinical Gastroenterol Hepatol.* 2007;5:964-968
56. DuPont HL, **Jiang ZD**, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, DuPont MW, Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. *Clinical Gastroenterology and Hepatology* 2007;5:451-456
57. DuPont HL, Haake R, Taylor DN, Ericsson CD, **Jiang ZD**, Okhuysen PC, Steffen R. Rifaximin treatment of pathogen-negative travelers' diarrhea. *Journal of Travel Medicine* 2007;14:16-19
58. DuPont HL, **Jiang ZD**. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and *enterococci*. *Clinical Microbiology and Infectious* 2004;10:1009-1011
59. Nair P, Mohamed JA, DuPont HL, Figueroa JF, Carlin LG, **Jiang ZD**, Belkind-Gerson J, Martinez-Sandoval FG, Okhuysen PC. Epidemiology of cryptosporidiosis in North American travelers to Mexico. *American Journal of Tropical Medicine and Hygiene* 2008;79:210-214
60. Garey KW, **Jiang ZD**, Yadav Y, Mullins B, Wong K, DuPont HL. Peripartum *Clostridium difficile* infection: case series and review of the literature. *American Journal of Obstetrics & Gynecology.* 2008;199:332-337
61. Frech SA, DuPont HL, Bourgeois AL, McKenzie R, Belkind-Gerson J, Figueroa JF, Okhuysen PC, Guerrero NH, Martinez-Sandoval FG, Meléndez-Romero JH, **Jiang ZD**, Asturias EJ, Halpern J, Torres OR, Hoffman AS, Villar CP, Kassem RN, Flyer DC, Andersen BH, Kazempour K, Breisch SA, Glenn GM. Use of a patch containing heat-labile toxin from *Escherichia coli* against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. *Lancet.* 2008;371:2019-2025.

62. Koo HL, **Jiang ZD**, Brown E, Garcia C, Qi H, DuPont HL. Coliform contamination of vegetables obtained from popular restaurants in Guadalajara, Mexico, and Houston, Texas. *Clinical Infectious Diseases* 2008;47:218-221
63. Garey KW, Dao-Tran TK, **Jiang ZD**, Price MP, Gentry LO, DuPont HL. A clinical risk index for *Clostridium difficile* infection in hospitalized patients receiving broad-spectrum antibiotics. *J Hosp Infect* 2008;70:142-147
64. Flores J, DuPont HL, **Jiang ZD**, Belkind-Gerson J, Mohamed JA, Carlin LG, Padda RS, Paredes M, Martinez-Sandoval JF, Villa NA, Okhuysen PC. Enterotoxigenic *Escherichia coli* heat-labile toxin seroconversion in US travelers to Mexico. *Journal of Travel Medicine* 2008;15:156-161
65. Grimes KA, Mohamed JA, DuPont HL, Padda RS, **Jiang ZD**, Flores J, Belkind-Gerson J, Martinez-Sandoval FG, Okhuysen PC. PCR-based assay using occult blood detection cards for detection of diarrheagenic *Escherichia coli* in specimens from U.S. travelers to Mexico with acute diarrhea. *Journal of Clinical Microbiology* 2008;46:2227-2230
66. Shen BO, **Jiang ZD**, Fazio VW, Remzi FH, Rodriguez L, Bennett AE, Lopez R, Queener E, DuPont HL. *Clostridium difficile* infection in patients with ileal pouch-anal anastomosis. *Clinical Gastroenterology and Hepatology* 2008;6:782-788
67. Meraz IM, Jiang ZD, Ericsson CD, Bourgeois AL, Steffen R, Taylor DN, Hernandez N, DuPont HL. Enterotoxigenic *Escherichia coli* and diffusely adherent *E. coli* as likely causes of a proportion of pathogen-negative travelers' diarrhea – a PCR-based study. *J Travel Med* 2008;15:412-418
68. Garey KW, **Jiang ZD**, Bellard A, DuPont HL. Rifaximin in treatment of recurrent *Clostridium difficile*-associated diarrhea: an uncontrolled pilot study. *J Clin Gastroenterol*. *J Clin Gastroenterol* 2008;43:91-93
69. Mohamed JA, DuPont HL, **Jiang ZD**, Flores J, Carlin LG, Belkind-Gerson J, Martinez-Sandoval FG, Guo D, White AC Jr, Okhuysen PC. A single-nucleotide polymorphism in the gene encoding osteoprotegerin, an anti-inflammatory protein produced in response to infection with diarrheagenic *Escherichia coli*, is associated with an increased risk of nonsecretory bacterial diarrhea in North American travelers to Mexico. *J Infect Dis*. 2009;199:477-485
70. Galbadage T, **Jiang ZD**, DuPont HL. Improvement in detection of enterotoxigenic *Escherichia coli* in patients with travelers' diarrhea by increasing the number of *E. coli* colonies tested. *Am J Trop Med Hyg*. 2009;80:20-23
71. Koo HL, Ajami NJ, **Jiang ZD**, DuPont HL, Atmar RL, Lewis D, Byers P, Abraham P, Quijano RA, Musher DM, Young EJ. A nosocomial outbreak of norovirus infection masquerading as *Clostridium difficile* infection. *Clin Infect Dis*. 2009;48:e75-e77
72. Vigil KJ, **Jiang ZD**, Chen JJ, Palumbo KL, Galbadage T, Brown EL, Yiang J, Koo H, DuPont MW, Ericsson C, Adachi JA, DuPont HL. Coliform and *Escherichia coli* contamination of desserts served in public restaurants from Guadalajara, Mexico, and Houston, Texas. *Am J Trop Med Hyg*. 2009;80:606-608

73. Koo HL, Ajami NJ, **Jiang ZD**, Atmar RL, DuPont HL Norovirus infection as a cause of sporadic healthcare-associated diarrhoea. *J Hosp Infect.* 2009;72:185-187
74. Chongsuvivatwong V, Chariyalertsak S, McNeil E, Aiyarak S, Hutamai S, DuPont HL, **Jiang ZD**, Kalambaheti T, Tonyong W, Thitiphuree S, Steffen R. Epidemiology of travelers' diarrhea in Thailand. *J Travel Med.* 2009;16:179-185
75. Salazar M, Garey KW, **Jiang ZD**, Dao-Tran T, DuPont H. Changing *Clostridium difficile* infection testing and treatment trends at a large tertiary care teaching hospital. *Pharm World Sci.* 2009;31:565-571
76. **Jiang ZD**, Ke S, Dupont HL. Rifaximin-induced alteration of virulence of diarrhoea-producing *Escherichia coli* and *Shigella sonnei*. *Int J Antimicrob Agents.* 2010 Mar;35(3):278-81
77. Darkoh C, Lichtenberger LM, Ajami N, Dial EJ, **Jiang ZD**, DuPont HL. Bile acids improve the antimicrobial effect of rifaximin. *Antimicrob Agents Chemother.* 2010;54:3618-3624
78. Ajami N, Koo H, Darkoh C, Atmar RL, Okhuysen PC, **Jiang ZD**, Flores J, Dupont HL. Characterization of norovirus-associated traveler's diarrhea. *Clin Infect Dis.* 2010;15:51(2):123-130
79. Ouyang-Latimer J, Ajami NJ, **Jiang ZD**, Okhuysen PC, Paredes M, Flores J, Dupont HL. Biochemical and genetic diversity of enterotoxigenic *Escherichia coli* associated with diarrhea in United States students in Cuernavaca and Guadalajara, Mexico, 2004-2007. *J Infect Dis.* 2010;201:1831-1838
80. Martinez-Sandoval F, Ericsson CD, **Jiang ZD**, Okhuysen PC, Romero JH, Hernandez N, Forbes WP, Shaw A, Bortey E, DuPont HL. Prevention of travelers' diarrhea with rifaximin in US travelers to Mexico. *J Travel Med.* 2010;17:111-117
81. **Jiang ZD**, DuPont HL, La Rocco M, Garey KW. In vitro susceptibility of *Clostridium difficile* to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. *J Clin Pathol.* 2010;63:355-358
82. Garey KW, **Jiang ZD**, Ghantaji S, Tam VH, Arora V, Dupont HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent *Clostridium difficile* infection. *Clin Infect Dis.* 2010;51:1406-10
83. Koo HL, Ajami NJ, **Jiang ZD**, Neill FH, Atmar RL, Ericsson CD, Okhuysen PC, Taylor DN, Bourgeois AL, Steffen R, DuPont HL Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. *J Clin Microbiol.* 2010;48:1673-1676
84. **Jiang ZD**, Dupont HL, Brown EL, Nandy RK, Ramamurthy T, Sinha A, Ghosh S, Guin S, Gurleen K, Rodrigues S, Chen JJ, McKenzie R, Steffen R. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic *Bacteroides fragilis* and *Arcobacter* species. *J Clin Microbiol.* 2010 ;48:1417-1419

85. Brown EL, Xue Q, **Jiang ZD**, Xu Y, Dupont HL. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. *Antimicrob Agents Chemother.* 2010;54:388-396
86. Flores J, Dupont HL, **Jiang ZD**, Okhuysen PC, Melendez-Romero JH, Gonzalez-Estrada A, Carrillo I, Paredes M. A randomized, double-blind, pilot study of rifaximin 550 mg versus placebo in the prevention of travelers' diarrhea in Mexico during the dry season. *J Travel Med.* 2011;18:333-336
87. Mohamed JA, DuPont HL, Flores J, Palur H, Nair P, **Jiang ZD**, Guo D, Belkind-Gerson J, Okhuysen PC. Single nucleotide polymorphisms in the promoter of the gene encoding the lipopolysaccharide receptor CD14 are associated with bacterial diarrhea in US and Canadian travelers to Mexico. *Clin Infect Dis.* 2011;52:1332-1341
88. Villa NA, Okhuysen PC, Flores-Figueroa J, **Jiang ZD**, Belkind-Gerson J, Paredes M, Mohamed JA, Nair P, Carlin L, DuPont HL. *Campylobacter jejuni* is not an important pathogen as a cause of diarrhea in US travelers to Mexico. *J Travel Med.* 2011;18:56-58
89. Ouyang-Latimer J, Jafri S, VanTassel A, **Jiang ZD**, Gurleen K, Rodriguez S, Nandy RK, Ramamurthy T, Chatterjee S, McKenzie R, Steffen R, DuPont HL. In vitro antimicrobial susceptibility of bacterial enteropathogens isolated from international travelers to Mexico, Guatemala, and India from 2006 to 2008. *Antimicrob Agents Chemother.* 2011;55:874-878
90. Garey KW, Ghantaji SS, Shah DN, Habib M, Arora V, **Jiang ZD**, DuPont HL. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with *Clostridium difficile* infection *J Antimicrob Chemother.* 2011 Sep 21
91. Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, **Jiang ZD**, DuPont UL, Shah VH. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. *J Hepatol* 2012;56:893-899
92. Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, **Jiang ZD**, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW. Multidrug resistance is common in *Escherichia coli* associated with ileal Crohn's disease. *Inflamm Bowel Dis.* 2011;19:141-50
93. **Jiang ZD**, Hoang L, Lasco T, Garey K, DuPont HL. Physician attitudes towards the use of fecal transplantation for recurrent *Clostridium difficile* infection in a large metropolitan city. *Clin Infect Dis.* 2013;56:1059-60
94. Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, **Jiang ZD**, Dupont HL. Efficacy and safety of a patch vaccine containing heat-labile toxin from *Escherichia coli* against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. *Lancet Infect Dis.* 2013;S1473:181-5

95. Huang JS, **Jiang ZD**, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of *Clostridium difficile*. *Antimicrob Agents Chemother*. 2013;57:2690-3
96. Youmans BP, Ajami NJ, **Jiang ZD**, Petrosino JF, Dupont HL, Highlander SK. Development and Accuracy of Quantitative Real-Time Polymerase Chain Reaction Assays for Detection and Quantification of Enterotoxigenic *Escherichia coli* (ETEC) Heat Labile and Heat Stable Toxin Genes in Travelers' Diarrhea Samples. *Am J Trop Med Hyg*. 2013 Nov 4.
97. Steffen R, Cramer JP, Burchard G, Jelinek T, Schwarz U, Ramdas P, Chatterjee S, **Jiang ZD**, DuPont HL, Dewasthaly S, Westritschnig K, Behrens RH. Efficacy of a travelers' diarrhea vaccine system in travelers to India. *J Travel Med*. 2013;20:374-9
98. Han XH, **Jiang ZD**, Du CX, Zhang CL, Zheng CL, Wang L, Li D, Feng Y, Dupont HL, Shi YK. *Clostridium difficile* infection in hospitalized cancer patients in Beijing, China is facilitated by receipt of cancer chemotherapy. *Anaerobe*. 2013;24:82-4
99. Darkoh C, Turnwald BP, Koo HL, Garey KW, **Jiang ZD**, Aitken SL, DuPont HL. Colonic immunopathogenesis of *Clostridium difficile* infections. *Clin Vaccine Immunol*. 2014;21:509
100. Ajami NJ, Kavanagh OV, Ramani S, Crawford SE, Atmar RL, **Jiang ZD**, Okhuysen PC, Estes MK, DuPont HL. Seroepidemiology of norovirus-associated travelers' diarrhea. *J Travel Med*. 2014;21:6
101. Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, **Jiang ZD**, DuPont HL. Efficacy and safety of a patch vaccine containing heat-labile toxin from *Escherichia coli* against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. *Lancet Infect Dis*. 2014;14(3):197
102. DuPont AW, **Jiang ZD**, Harold SA, Snyder N, Galler GW, Garcia-Torres F, DuPont HL. Motility abnormalities in irritable bowel syndrome. *Digestion*. 2014;89:119
103. Koo HL, Van JN, Zhao M, Ye X, Revell PA, **Jiang ZD**, Grimes CZ, Koo DC, Lasco T, Kozinetz CA, Garey KW, DuPont HL. Real-time polymerase chain reaction detection of asymptomatic *Clostridium difficile* colonization and rising *C. difficile*-associated disease rates. *Infect Control Hosp Epidemiol*. 2014;35:667
104. Nair P, Okhuysen PC, **Jiang ZD**, Carlin LG, Belkind-Gerson J, Flores J, Paredes M, DuPont HL. Persistent abdominal symptoms in US adults after short-term stay in Mexico. *J Travel Med*. 2014;21:153

105. Qu HQ, **Jiang ZD**. *Clostridium difficile* infection in diabetes. *Diabetes Res Clin Pract*. 2014;105:285
106. Crews JD, Koo HL, **Jiang ZD**, Starke JR, DuPont HL. A Hospital-based Study of the Clinical Characteristics of *Clostridium difficile* Infection in Children. *Pediatr Infect Dis J*. 2014;33:924
107. DuPont HL, Petersen A, Zhao J, Mundt A, **Jiang ZD**, Miller S, Flores J, Shringarpure R, Moro L, Bagin RG, Ballard ED, Totoritis MC. Targeting of Rifamycin SV to the Colon for Treatment of Travelers' Diarrhea: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. *J Travel Med*. 2014;21:369
108. Youmans BP, Ajami NJ, **Jiang ZD**, Campbell F, Wadsworth WD, Petrosino JF, DuPont HL, Highlander SK. Characterization of the human gut microbiome during travelers' diarrhea. *Gut Microbes*. 2015;6:110
109. **Jiang ZD**, Alexander A, Ke S, Valilis EM, Hu S, Li B, DuPont H. Stability and efficacy of frozen and lyophilized fecal microbiota transplant (FMT) product in a mouse model of *Clostridium difficile* infection (CDI). *Anaerobe*. 2017;S1075-9964(17)30162-2
110. **Jiang ZD**, DuPont HL. Etiology of travellers' diarrhea. *J Travel Med*. 2017;24:S13-S16
111. **Jiang ZD**, Ajami NJ, Petrosino JF, Jun G, Hanis CL, Shah M, Hochman L, Ankoma-Sey V, DuPont AW, Wong MC, Alexander A, Ke S, DuPont HL. Randomised clinical trial: faecal microbiota transplantation for recurrent *Clostridium difficile* infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. *Aliment Pharmacol Ther*. 2017;45:899-908
112. Kharat VB, Ahmed M, **Jiang ZD**, Riddle MS, DuPont HL. Colonization Factors in Enterotoxigenic *Escherichia coli* Strains in Travelers to Mexico, Guatemala, and India Compared with Children in Houston, Texas. *Am J Trop Med Hyg*. 2017;96:83-87.
113. Nicholson MR, Crews JD, Starke JR, **Jiang ZD**, DuPont H, Edwards K. Recurrent *Clostridium difficile* Infection in Children: Patient Risk Factors and Markers of Intestinal Inflammation. *Pediatr Infect Dis J*. 2017;36:379-383
114. **Jiang ZD**, Jenq RR, Ajami NJ, Petrosino JF, Alexander AA, Ke S, Iqbal T, DuPont AW, Muldrew K, Shi Y, Peterson CB, Do K, DuPont HL. Preliminary Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product Compared with Frozen Product Given by Enema for Recurrent *Clostridium difficile* Infection: A Randomized Clinical Trial. *PLoS One*. 2018 Nov 2;13(11):e0205064
115. Zhu Q, Dupont CL, Jones MB, Pham KM, **Jiang ZD**, DuPont HL, Highlander SK Visualization-assisted binning of metagenome assemblies reveals potential new pathogenic profiles in idiopathic travelers' diarrhea. *Microbiome*. 2018 Nov 8;6(1):201
116. Dogan B, Belcher-Timme HF, Dogan EI, **Jiang ZD**, DuPont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KWEvaluation of *Escherichia coli* pathotypes associated with irritable bowel syndrome. *FEMS Microbiol Lett*. 2018 Nov 1;365(22). doi: 10.1093/femsle/fny249

117. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, **Jiang ZD**, Abu-Sbeih H, Sanchez CA, Chang CC, Parra ER, Francisco-Cruz A, Raju GS, Stroehlein JR, Campbell MT, Gao J, Subudhi SK, Maru DM, Blando JM, Lazar AJ, Allison JP, Sharma P, Tetzlaff MT, Wargo JA, Jenq RR Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. *Nat Med.* 2018 Dec;24(12):1804-1808
118. Bamidele O, **Jiang ZD**, DuPont HL. Occurrence of putative virulence-related genes, *aatA*, *aggR* and *aaiC*, of Enteroaggregative *Escherichia coli* (EAEC) among adults with travelers' diarrhea acquired in Guatemala and Mexico. *Microb Pathog.* 2019 Mar;128:97-99
119. Hibbard J, **Jiang ZD**, DuPont HL. Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent *Clostridium difficile* infection. *Anaerobe.* 2019 Apr;56:102-105. doi: 10.1016/j.anaerobe.2019.03.006